|
Jack Gauldie, pathology & molecular medicine.
Jack Gauldie
Gene therapeutics – the use of the gene as a drug –
is expected to revolutionize health care, leading to advances in
preventing, diagnosing and treating diseases from asthma to cancer.
At the forefront of this research is Dr. Jack Gauldie, chair of
pathology and molecular medicine.
|
 |
 |
An expert in cytokine biology, inflammation and immunology,
Gauldie is director of McMaster’s Centre for Gene Therapeutics.
Since 1997, the Centre has teamed up the University with local
hospitals to work on creating and implementing state-of-the-art
gene transfer therapies for cancer and inflammatory and infectious
diseases.
Gauldie will also be the lead investigator for McMaster’s
new Institute for Molecular Medicine and Health, which has
received some$25-million in federal and provincial funding.
A Fellow of the Royal Society of Canada, he hopes to see
gene therapeutics become as cheap and effective in preventing
and treating chronic degenerative illness as vaccination has
been in preventing infectious disease.
<
BACK TO FACES
OF INNOVATION |
|
